Did you know?

The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ...See the latest TransCode Therapeutics Inc stock price (RNAZ:XNAS), related news, valuation, dividends and more to help you make your investing decisions.BOSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules Read full article TransCode Therapeutics, Inc.TransCode Therapeutics has also granted underwriters of the offering a 45-day option to acquire another 2,339,200 shares. These will be priced the same as the shares included in the public stock ... TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, …TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, …TransCode Therapeutics Announces Public Offering of Common Stock. October 26, 2023. PDF Version. BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an ...According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each. This has the company expecting to raise $8 million in gross proceeds from the ...BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that it is withdrawing the underwritten public offering of its common stock. This reflects the Company’s belief …Sep 25, 2023 · RNAZ stock soared on the possible implications of addressing brain tumors. Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ: RNAZ) saw its shares drive up 300% ... TransCode Therapeutics stock skyrockets on positive brain cancer trial results. Proactive Investors • 09/25/23. TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138. GlobeNewsWire • …TransCode Therapeutics, Inc. (RNAZ) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 0.2190 -0.0270 (-10.98%) At close: 04:00PM EST 0.2210 +0.00 (+0.91%) After hours: 07:59PM...Transcode Therapeutics stock price gapped 62.83% higher to trade at 4.25, rising from Wednesday’s closing price of $2.61. Should You Invest in Transcode Therapeutics Shares? One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have …TransCode Therapeutics Inc. Watch list NEW Set a price targDec 6, 2022 · TransCode Therapeutics, Inc. 0.2328. -0.0071. -2.96 About TransCode Therapeutics TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its iron oxide nanoparticle delivery platform, the Company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of … The Trade: TransCode Therapeutics, Inc. RNAZ CEO Michael Robert Dud The shares of common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268764) previously filed with the Securities and ... Find the latest historical data for TransC

TransCode expects that its cash of approximately $5.0 million as of December 31, 2022, together with approximately $1.3M in net proceeds received from the sale of common stock in its February 2023 registered direct offering and $871 thousand of additional funding expected in the second quarter of 2023 for the third year of its SBIR award will ...TransCode Therapeutics ( NASDAQ: RNAZ) said that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares …TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has closed a registered direct offering, selling 5,000,000 shares of common stock at $0.242 per share, resulting in gross proceeds of $1.2 million. The company plans to use the net proceeds for clinical trials with its lead therapeutic candidate, TTX-MC138, and for general corporate purposes.TransCode Therapeutics Announces Public Offering of Common Stock. BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology ...Quick Take. TransCode Therapeutics ( NASDAQ: RNAZ) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement. The company is ...

TransCode Therapeutics Market Cap: 697.84K, Enterprise value: N/A, P/E: -0.34, PEG ratio: N/A, EPS: -6.95, Revenue: N/A, EBITDA: -18.29M, Income: -31.18M, ...Dec 4, 2023 · The consensus among analysts is that TransCode Therapeutics Inc (RNAZ) is a Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. 27 thg 9, 2023 ... ... Stock TONR Stock FAMI Stock XELA. Possible cause: BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the.